FDA accepts NDA for Cosmo's diagnostic

Cosmo Pharmaceuticals N.V. (SIX:COPN) said FDA accepted for review an NDA for Methylene Blue MMX (CB-17-01) to detect lesions, polyps and adenomas in the colon. Its PDUFA date is May 21, 2018...